Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SynKIR-310 in Non-Hodgkin's lymphoma refractory: NCT06544265 Clinical Landscape Report 2026
15 October 2026
NCT06544265 clinical landscape for Non-Hodgkin's lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Igermetostat Maleate in Follicular Lymphoma: NCT06558513 Clinical Landscape Report 2026
15 October 2026
NCT06558513 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in High grade B-cell lymphoma: NCT06550141 Clinical Landscape Report 2026
15 October 2026
NCT06550141 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trigriluzole in Glioblastoma, IDH-Wildtype: NCT06552260 Clinical Landscape Report 2026
15 October 2026
NCT06552260 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bendamustine Hydrochloride in Diffuse large B-cell lymphoma recurrent: NCT06554600 Clinical Landscape Report 2026
15 October 2026
NCT06554600 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Pembrolizumab in Recurrent Glioblastoma: NCT06558214 Clinical Landscape Report 2026
15 October 2026
NCT06558214 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imdatifan in Von Hippel-Lindau Disease: NCT06553339 Clinical Landscape Report 2026
15 October 2026
NCT06553339 clinical landscape for Von Hippel-Lindau Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in Diffuse large B-cell lymphoma recurrent: NCT06552572 Clinical Landscape Report 2026
15 October 2026
NCT06552572 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Flucytosine in Glioblastoma Multiforme: NCT06562621 Clinical Landscape Report 2026
15 October 2026
NCT06562621 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06556563 Clinical Landscape Report 2026
15 October 2026
NCT06556563 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RAG-17 in Amyotrophic Lateral Sclerosis: NCT06556394 Clinical Landscape Report 2026
15 October 2026
NCT06556394 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLPG-5101 in High grade B-cell lymphoma: NCT06561425 Clinical Landscape Report 2026
15 October 2026
NCT06561425 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.